Experimental Drug Targets Lung Damage and Fatal Blood Clots Caused by CCP Virus

This 2020 electron microscope image made available by the U.S. Centers for Disease Control and Prevention shows the spherical particles of the new coronavirus, colorized blue, from the first U.S. case of COVID-19. AP-Hannah A. Bullock, Azaibi Tamin/CDC via AP/The Canadian Press

Up to a third of the hospitalized CCP virus patients who are seriously ill are developing dangerous blood clots, according to a study conducted in the Netherlands, and an experimental drug to prevent them is about to be trialed in the United Kingdom.

The drug, a molecule known as TRV027, is set to be trialed in 60 patients with confirmed or suspected infection in hospitals in the United Kingdom, according to a release.